Provided by Tiger Trade Technology Pte. Ltd.

Palvella Therapeutics

145.75
+3.712.61%
Post-market: 145.750.00000.00%19:30 EDT
Volume:315.52K
Turnover:44.70M
Market Cap:2.10B
PE:-29.76
High:146.69
Open:141.78
Low:136.06
Close:142.04
52wk High:161.38
52wk Low:49.13
Shares:14.41M
Float Shares:8.40M
Volume Ratio:1.71
T/O Rate:3.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.8978
EPS(LYR):-3.7076
ROE:-46.63%
ROA:-22.05%
PB:9.68
PE(LYR):-39.31

Loading ...

Palvella Therapeutics selloff a buying opportunity, says BTIG

TIPRANKS
·
Jul 21

U.S. Small Caps Decrease; Palvella Therapeutics Falls Furthest

Dow Jones
·
Jul 21

Palvella Therapeutics falls -9.0%

TIPRANKS
·
Jul 20

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Armata Pharmaceuticals (ARMP)

TIPRANKS
·
Jul 20

Palvella Therapeutics COO Kathleen Goin Disposes of 4,302 Common Shares Worth $642,194.57

Reuters
·
Jul 18

Palvella Therapeutics Highlights Growth Plans and QTORIN Progress

TIPRANKS
·
Jul 15

Palvella Therapeutics Director Matthew Pauls Files Initial Beneficial Ownership Statement

Reuters
·
Jul 02

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bio-Techne (TECH), Concentra Group Holdings Parent, Inc. (CON) and Palvella Therapeutics (PVLA)

TIPRANKS
·
Jul 01

Palvella Therapeutics Adds Industry Veteran to Board

TIPRANKS
·
Jun 30

Palvella Therapeutics Appoints Savara CEO Matt Pauls to Board of Directors

Reuters
·
Jun 30

Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.d., M.b.a., to Board of Directors

THOMSON REUTERS
·
Jun 30

Palvella submits first rolling new drug application to FDA for Qtorin

TIPRANKS
·
Jun 29

Palvella Submits First NDA Module to FDA for Qtorin Rapamycin Under Rolling Review

Reuters
·
Jun 29

Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for Qtorin™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

THOMSON REUTERS
·
Jun 29

Palvella Therapeutics - Expects to Complete Nda Submission in H2 2026

THOMSON REUTERS
·
Jun 29

Analysts Are Bullish on These Healthcare Stocks: Palvella Therapeutics (PVLA), Verastem (VSTM)

TIPRANKS
·
Jun 24

Palvella Therapeutics COO Kathleen Goin reports common stock sale worth $475,137.71

Reuters
·
Jun 23

Craig-Hallum Reaffirms Their Buy Rating on Palvella Therapeutics (PVLA)

TIPRANKS
·
Jun 22

Palvella Therapeutics' Qtorin Granted FDA Rolling Review; Shares Rise Pre-Bell

MT Newswires Live
·
Jun 22

FDA grants rolling review to Palvella Therapeutics Qtorin rapamycin

TIPRANKS
·
Jun 22